FindTrial
Sign In

Real world study on the efficacy of COVID-19 vaccine in patients with liver disease

Real world study on the efficacy of COVID-19 vaccine in patients with liver disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046936
Enrollment
Unknown
Registered
2021-05-31
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver disease

Interventions

Case series:None

Sponsors

the First Affliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis of patients with liver disease; 2. At least one new coronary pneumonia vaccine has been injected; 3. The vaccination procedure complies with the technical guidelines for the new crown vaccination of the Health Commission.

Exclusion criteria

Exclusion criteria: 1. Patients with uncontrollable heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal serious primary diseases; 2. Patients with mental illness, children, the elderly, or those who cannot cooperate; 3. The researcher believes that it is not appropriate to be selected for this trial.

Design outcomes

Primary

MeasureTime frame
Blood routine;Liver function;Coagulation;HBsAg quantification;HBV DNA quantification;Liver stiffness measurement;Control decay index;COVID-19 antibody;Color Doppler ultrasound of upper abdomen;—

Countries

China

Contacts

Public ContactLiang Hongxia

the First Affliated Hospital of Zhengzhou University

hxliang@zzu.edu.cn+86 15039075158

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026